Q1 EPS Forecast for Bicara Therapeutics Decreased by Analyst

Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Analysts at Wedbush reduced their Q1 2025 earnings per share estimates for Bicara Therapeutics in a research report issued to clients and investors on Thursday, March 27th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.40) per share for the quarter, down from their prior estimate of ($0.33). Wedbush currently has a "Outperform" rating and a $31.00 target price on the stock. The consensus estimate for Bicara Therapeutics' current full-year earnings is ($2.59) per share. Wedbush also issued estimates for Bicara Therapeutics' Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.67) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($1.87) EPS and FY2027 earnings at ($2.10) EPS.

Several other research firms have also weighed in on BCAX. HC Wainwright upped their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, January 27th. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 target price on shares of Bicara Therapeutics in a report on Thursday, March 13th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $36.67.

Remove Ads

Bicara Therapeutics Trading Down 10.8 %

Shares of BCAX stock traded down $1.43 during trading hours on Monday, hitting $11.83. The company had a trading volume of 662,788 shares, compared to its average volume of 469,631. Bicara Therapeutics has a 12 month low of $11.10 and a 12 month high of $28.09. The firm's fifty day moving average is $13.09 and its 200 day moving average is $17.69.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08).

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System bought a new stake in shares of Bicara Therapeutics during the fourth quarter worth approximately $25,000. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $31,000. BNP Paribas Financial Markets acquired a new position in shares of Bicara Therapeutics in the 4th quarter valued at $32,000. Legal & General Group Plc bought a new position in shares of Bicara Therapeutics in the 4th quarter worth $33,000. Finally, Summit Investment Advisors Inc. bought a new position in Bicara Therapeutics during the fourth quarter worth about $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.